| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() HIV And Cancer Patients Not Abusing THC-Derived Drug, Researchers Say CHICAGO, IL -- June 18, 1998 -- San Francisco researchers evaluating clinicians' experiences with Unimed Pharmaceuticals, Inc.’s Marinol(R) (dronabinol) found no observed cases of abuse among patients, confirming its safety in the treatment of appetite loss in people with HIV and vomiting and nausea in people with cancer. Study findings were presented today by Sarah Calhoun, president and research director, Haight Ashbury Free Clinics, Inc., San Francisco, in conjunction with the College of Problems of Drug Dependency's annual scientific meeting being held in Scottsdale, AZ. Marinol is the only legally-available synthetic form of THC, the primary psychoactive component present in Cannabis sativa L. (marijuana). The new Marinol study, which was conducted nation-wide over a nine-month period, included the collection of experiences among researchers, physicians, addiction medicine specialists and law enforcement personnel. "This study can help allay the fears of some clinicians and patients who may be worried about the dangers of using a product like Marinol," Calhoun said. "We feel this product has very low abuse potential." Among the findings: More information on: Marinol, Unimed Pharmaceuticals, Inc.
|